ProCE Banner Activity

Managing Patients With Myelofibrosis Following Ruxolitinib Failure

Clinical Thought
Outcomes are poor for patients with myelofibrosis who discontinue ruxolitinib due to loss of response or intolerance. In this commentary, I offer my thoughts on the best treatment options for these patients.

Released: October 07, 2019

Expiration: October 05, 2020

Share

Faculty

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Celgene

CTI BioPharma Corp., a Sobi Company

Geron

Faculty Disclosure

Primary Author

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received funds for research support from Blueprint Medicines, Celgene, CTI BioPharma, Genentech, Gilead Sciences, Incyte, Novartis, NS Pharma, Promedior, and Roche and consulting fees from Celgene, Constellation, Incyte, Novartis, Pragmatist, and Sierra.